Neurogene Inc.
HealthcareNASDAQ:NGNE · NASDAQ Global Market
+$0.10 today
Vol 0.11M · Avg 0.16M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-34.1%
avg -25.9%
ROIC
-37.5%
avg -33.3%
ROA
-31.3%
avg -33.0%
Analysis
ROA is currently the strongest return metric at -31.3% versus its period average of -33.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Rachel L. McMinn | Founder, Executive Chair & Chief Executive Officer | $997,237.00 | — | 53 | $1.34M | 8.51% |
Christine Mikail Cvijic | President, CFO & Director | $874,062.00 | — | 48 | $98,440.00 | 0.62% |
Julie Jordan | Chief Medical Officer | $696,339.00 | — | 54 | $12,472.00 | 0.08% |
Stuart Cobb | Chief Scientific Officer | $478,807.00 | — | 55 | $33,303.00 | 0.21% |
Andrew E. Mulberg FAAP | Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control | — | — | — | — | — |
Arvind Sreedharan | Senior Vice President of Business Operations | — | — | — | — | — |
Ricardo Jimenez | Senior Vice President of Technical Operations | — | — | — | — | — |
Christina Shafer | Chief Commercial Officer | — | — | 50 | $120,000.00 | 0.76% |
Donna Cochener-Metcalfe | Senior Vice President, General Counsel & Corporate Secretary | — | — | 51 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
12
$793,630.08
Net Sentiment
$793,630.08
Net selling
Most Active
Cvijic Christine Mikail
7 transactions
1–10 of 12
Analysis
Insiders reported 0 buys worth $0.00 and 12 sells worth $793,630.08 over the last 12 months. That adds up to net selling of $793,630.08. Cvijic Christine Mikail was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Alumis Inc. Common Stock
NASDAQ:ALMS
$2.98B
Solid Biosciences Inc.
NASDAQ:SLDB
$556.28M
PureTech Health plc
NASDAQ:PRTC
$424.07M
Autolus Therapeutics plc
NASDAQ:AUTL
$415.18M
Ocugen, Inc.
NASDAQ:OCGN
$409.61M
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
$316.61M
Benitec Biopharma Inc.
NASDAQ:BNTC
$293.44M
Quantum-Si incorporated
NASDAQ:QSI
$187.28M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$186.68M
ADC Therapeutics S.A.
NYSE:ADCT
$133.55M
Who manages NGNE?
Neurogene Inc. (NGNE) lists 9 active executives. The top listed executive is Andrew E. Mulberg FAAP, Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control.
Are NGNE insiders buying or selling?
Recent insider activity shows net buying of $27.08M.
Explore More
Continue the stock analysis
Jump to another research area for this company.